Furthermore, the ROCK inhibitor, Fasudil, has been shown to decrease disease burden in myeloproliferative disease (MPD) mouse models27,65 and combination of imatinib with either Fasudil or the ROCK inhibitor Y-27632 showed synergistic inhibition of CD34+ chronic myeloid progenitor cell growth66. This evidence concerns the gene CD34 and myeloproliferative disorder.